Recent News
On August 5, 2025 the company reported second-quarter 2025 results and confirmed completion of the Sage Therapeutics acquisition on July 31, 2025, adding Zurzuvae and a CNS discovery platform to the portfolio and signaling expected accretion in 2026. A July 22, 2025 investor notice set the August 5 earnings date; management highlighted integration and the ONAPGO launch as priorities. Supernus announced participation in several September 2025 investor events. Coverage noted the Sage deal structure: $8.50 cash per share plus up to $3.50 in contingent payments tied to milestones.
Technical Analysis
Trend strength (ADX and directional indicators): ADX at 50.07 signals a very-strong trending environment; DI+ shows a peak-and-reversal (bearish) while DI- displays a dip-and-reversal (bearish). Together this implies directional strength exists but recent directional shifts favor downside momentum into the near term.
MACD momentum: MACD sits at 1.45 below its signal line at 1.89 with a decreasing MACD trend, which denotes weakening bullish momentum and favors short-term bearish momentum versus price averages.
MRO interpretation: MRO at 34.0 with a dip-and-reversal indicates the price sits above the modeled target and carries downward pressure; the oscillator’s positive value implies potential for price mean-reversion toward valuation anchors.
RSI and short-term reversal: RSI at 65.83 with a dip-and-reversal suggests recent strength has pulled the indicator high and that the immediate momentum has peaked, increasing probability of consolidation or pullback before resumption.
Price vs moving averages and Ichimoku: Last close $44.80 rests above the 200-day average $35.53, signaling longer-term bullish context, while trading below the 20-day average $45.31 and beneath the 12-day EMA $44.94 signals near-term pressure. The Chikou span sits above the Ichimoku cloud, which maintains bullish structural bias despite short-term weakness.
Bollinger and volatility context: Price near the lower Bollinger bands (lower 2x at $43.51) and price trend described as a dip & reversal below -2x standard deviation indicate a recent overshoot; lower immediate volatility combined with elevated ADX suggests moves may unfold decisively once momentum resolves.
Fundamental Analysis
Profitability and margins: Operating margin (EBITmargin) $0.07338 or 7.34% declined QoQ by -5.23% and YoY by -0.53%. That operating margin sits below the industry peer mean of 31.98% (industry peer mean) and below the industry peer median of 32.489% (industry peer median), indicating profitability remains modest versus peers even as revenues grow.
Revenue and earnings growth: Total revenue $165,453,000 shows YoY revenue growth of 10.43% and QoQ revenue growth of -1.75%. Net income $22,499,000 and EPS actual $0.40 beat the estimate of -$0.06 by $0.46, representing a roughly 767% surprise to the estimate.
Cash, leverage, and liquidity: Cash and short-term investments total $522,596,000, cash ratio 1.82 and current ratio 2.58, supporting flexibility for integration and launches. Total debt $31,774,000 yields debt-to-assets 2.30% and debt-to-EBITDA 0.95, indicating a low leverage profile relative to operational scale.
Cash flow and valuation anchors: Free cash flow $58,080,000 produces a free cash flow yield of 3.14%, above the industry peer mean of 1.72% (industry peer mean), while cash flow to earnings stands at 245%. Enterprise multiple 40.61 sits below the industry peer mean of 58.30 (industry peer mean), and WMDST values the stock as under-valued based on those cash-flow and enterprise metrics.
Pipeline and commercial drivers: Recent completion of the Sage acquisition brings Zurzuvae revenue participation and an expanded CNS discovery platform; ONAPGO launch and stronger Qelbree and GOCOVRI prescriptions underpinned revenue mix in the quarter. R&D remains active with SPN-817 in Phase 2b and other candidates advancing, which supports medium-term revenue optionality while raising near-term investment requirements.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-06-30 |
| REPORT DATE: | 2025-08-05 |
| NEXT REPORT DATE: | 2025-11-04 |
| CASH FLOW | Begin Period Cash Flow | $ 115.8 M |
| Operating Cash Flow | $ 58.5 M | |
| Capital Expenditures | $ -455.00 K | |
| Change In Working Capital | $ 11.5 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 28.9 M | |
| End Period Cash Flow | $ 144.7 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 165.5 M | |
| Forward Revenue | $ 48.7 M | |
| COSTS | ||
| Cost Of Revenue | $ 16.8 M | |
| Depreciation | $ 539.0 K | |
| Depreciation and Amortization | $ 21.4 M | |
| Research and Development | $ 22.1 M | |
| Total Operating Expenses | $ 153.3 M | |
| PROFITABILITY | ||
| Gross Profit | $ 148.6 M | |
| EBITDA | $ 33.5 M | |
| EBIT | $ 12.1 M | |
| Operating Income | $ 12.1 M | |
| Interest Income | $ 4.5 M | |
| Interest Expense | — | |
| Net Interest Income | $ 4.5 M | |
| Income Before Tax | $ 16.7 M | |
| Tax Provision | $ -5.83 M | |
| Tax Rate | 21.0 % | |
| Net Income | $ 22.5 M | |
| Net Income From Continuing Operations | $ 22.5 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.06 | |
| EPS Actual | $ 0.40 | |
| EPS Difference | $ 0.46 | |
| EPS Surprise | 766.667 % | |
| Forward EPS | $ 0.47 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 1.4 B | |
| Intangible Assets | $ 598.3 M | |
| Net Tangible Assets | $ 465.6 M | |
| Total Current Assets | $ 738.9 M | |
| Cash and Short-Term Investments | $ 522.6 M | |
| Cash | $ 144.7 M | |
| Net Receivables | $ 140.8 M | |
| Inventory | $ 44.0 M | |
| Long-Term Investments | $ 28.0 M | |
| LIABILITIES | ||
| Accounts Payable | $ 8.2 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 286.4 M | |
| Net Debt | — | |
| Total Debt | $ 31.8 M | |
| Total Liabilities | $ 318.5 M | |
| EQUITY | ||
| Total Equity | $ 1.1 B | |
| Retained Earnings | $ 567.1 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 18.96 | |
| Shares Outstanding | 56.119 M | |
| Revenue Per-Share | $ 2.95 | |
| VALUATION | Market Capitalization | $ 1.9 B |
| Enterprise Value | $ 1.4 B | |
| Enterprise Multiple | 40.613 | |
| Enterprise Multiple QoQ | -48.897 % | |
| Enterprise Multiple YoY | 54.046 % | |
| Enterprise Multiple IPRWA | high: 108.842 mean: 58.295 median: 49.313 SUPN: 40.613 low: -69.016 |
|
| EV/R | 8.223 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.299 | |
| Asset To Liability | 4.34 | |
| Debt To Capital | 0.029 | |
| Debt To Assets | 0.023 | |
| Debt To Assets QoQ | -4.17 % | |
| Debt To Assets YoY | 212.228 % | |
| Debt To Assets IPRWA | high: 0.823 mean: 0.344 median: 0.313 SUPN: 0.023 low: 0.002 |
|
| Debt To Equity | 0.03 | |
| Debt To Equity QoQ | -4.69 % | |
| Debt To Equity YoY | 195.45 % | |
| Debt To Equity IPRWA | high: 3.571 mean: 1.196 median: 0.734 SUPN: 0.03 low: -2.461 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 1.74 | |
| Price To Book QoQ | -2.781 % | |
| Price To Book YoY | 5.639 % | |
| Price To Book IPRWA | high: 12.536 median: 5.087 mean: 4.348 SUPN: 1.74 low: -3.191 |
|
| Price To Earnings (P/E) | 82.473 | |
| Price To Earnings QoQ | -152.562 % | |
| Price To Earnings YoY | 3.625 % | |
| Price To Earnings IPRWA | high: 189.74 SUPN: 82.473 mean: 65.538 median: 55.693 low: -17.582 |
|
| PE/G Ratio | -0.284 | |
| Price To Sales (P/S) | 11.189 | |
| Price To Sales QoQ | -9.129 % | |
| Price To Sales YoY | 19.421 % | |
| Price To Sales IPRWA | high: 42.852 mean: 20.728 median: 16.814 SUPN: 11.189 low: 0.964 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | 68.68 | |
| Forward PE/G | -0.236 | |
| Forward P/S | 37.977 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | -54.42 | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.121 | |
| Asset Turnover Ratio QoQ | 9.85 % | |
| Asset Turnover Ratio YoY | -5.665 % | |
| Asset Turnover Ratio IPRWA | high: 0.283 mean: 0.136 median: 0.136 SUPN: 0.121 low: 0.008 |
|
| Receivables Turnover | 1.155 | |
| Receivables Turnover Ratio QoQ | 10.912 % | |
| Receivables Turnover Ratio YoY | 3.014 % | |
| Receivables Turnover Ratio IPRWA | high: 2.644 mean: 1.288 median: 1.228 SUPN: 1.155 low: 0.459 |
|
| Inventory Turnover | 0.36 | |
| Inventory Turnover Ratio QoQ | 18.483 % | |
| Inventory Turnover Ratio YoY | 43.964 % | |
| Inventory Turnover Ratio IPRWA | high: 1.248 mean: 0.49 median: 0.4 SUPN: 0.36 low: 0.19 |
|
| Days Sales Outstanding (DSO) | 78.997 | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | 305.223 | |
| Cash Conversion Cycle Days QoQ | 22.8 % | |
| Cash Conversion Cycle Days YoY | -28.829 % | |
| Cash Conversion Cycle Days IPRWA | high: 506.721 SUPN: 305.223 mean: 161.138 median: 133.678 low: -339.4 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.366 | |
| CapEx To Revenue | -0.003 | |
| CapEx To Depreciation | -0.844 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.1 B | |
| Net Invested Capital | $ 1.1 B | |
| Invested Capital | $ 1.1 B | |
| Net Tangible Assets | $ 465.6 M | |
| Net Working Capital | $ 452.5 M | |
| LIQUIDITY | ||
| Cash Ratio | 1.825 | |
| Current Ratio | 2.58 | |
| Current Ratio QoQ | 5.737 % | |
| Current Ratio YoY | 34.753 % | |
| Current Ratio IPRWA | high: 4.744 SUPN: 2.58 mean: 1.063 median: 1.006 low: 0.074 |
|
| Quick Ratio | 2.426 | |
| Quick Ratio QoQ | 7.138 % | |
| Quick Ratio YoY | 43.243 % | |
| Quick Ratio IPRWA | SUPN: 2.426 high: 2.377 mean: 0.808 median: 0.758 low: 0.195 |
|
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | 0.949 | |
| Cost Of Debt | 0.0 % | |
| Interest Coverage Ratio | — | |
| Interest Coverage Ratio QoQ | — | |
| Interest Coverage Ratio YoY | — | |
| Interest Coverage Ratio IPRWA | — | |
| Operating Cash Flow Ratio | 0.193 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | 44.247 | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 2.606 % | |
| Revenue Growth | 10.432 % | |
| Revenue Growth QoQ | -174.658 % | |
| Revenue Growth YoY | -39.285 % | |
| Revenue Growth IPRWA | high: 38.515 % SUPN: 10.432 % mean: 10.344 % median: 8.267 % low: -9.726 % |
|
| Earnings Growth | -290.476 % | |
| Earnings Growth QoQ | 126.934 % | |
| Earnings Growth YoY | -855.229 % | |
| Earnings Growth IPRWA | high: 88.922 % mean: 23.238 % median: 5.882 % low: -114.286 % SUPN: -290.476 % |
|
| MARGINS | ||
| Gross Margin | 89.83 % | |
| Gross Margin QoQ | 0.392 % | |
| Gross Margin YoY | 0.53 % | |
| Gross Margin IPRWA | high: 90.656 % SUPN: 89.83 % median: 77.496 % mean: 76.119 % low: -8.482 % |
|
| EBIT Margin | 7.338 % | |
| EBIT Margin QoQ | -523.428 % | |
| EBIT Margin YoY | -53.04 % | |
| EBIT Margin IPRWA | high: 74.453 % median: 32.489 % mean: 31.98 % SUPN: 7.338 % low: -147.563 % |
|
| Return On Sales (ROS) | 7.338 % | |
| Return On Sales QoQ | -523.428 % | |
| Return On Sales YoY | -53.04 % | |
| Return On Sales IPRWA | high: 45.805 % median: 35.126 % mean: 34.856 % SUPN: 7.338 % low: -127.832 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ 58.1 M | |
| Free Cash Flow Yield | 3.137 % | |
| Free Cash Flow Yield QoQ | 91.164 % | |
| Free Cash Flow Yield YoY | 39.113 % | |
| Free Cash Flow Yield IPRWA | high: 9.075 % SUPN: 3.137 % mean: 1.716 % median: 0.943 % low: -11.204 % |
|
| Free Cash Growth | 91.86 % | |
| Free Cash Growth QoQ | -391.619 % | |
| Free Cash Growth YoY | -1451.677 % | |
| Free Cash Growth IPRWA | high: 563.847 % SUPN: 91.86 % mean: 16.92 % median: -26.3 % low: -616.923 % |
|
| Free Cash To Net Income | 2.581 | |
| Cash Flow Margin | 33.368 % | |
| Cash Flow To Earnings | 2.454 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.04 | |
| Return On Assets (ROA) | 1.648 % | |
| Return On Assets QoQ | -289.208 % | |
| Return On Assets YoY | 8.421 % | |
| Return On Assets IPRWA | high: 5.949 % median: 3.806 % mean: 3.524 % SUPN: 1.648 % low: -11.289 % |
|
| Return On Capital Employed (ROCE) | 1.108 % | |
| Return On Equity (ROE) | 0.021 | |
| Return On Equity QoQ | -284.394 % | |
| Return On Equity YoY | 1.683 % | |
| Return On Equity IPRWA | high: 0.31 mean: 0.146 median: 0.096 SUPN: 0.021 low: -0.281 |
|
| DuPont ROE | 2.148 % | |
| Return On Invested Capital (ROIC) | 0.902 % | |
| Return On Invested Capital QoQ | -697.351 % | |
| Return On Invested Capital YoY | -115.291 % | |
| Return On Invested Capital IPRWA | high: 12.214 % mean: 6.42 % median: 5.567 % SUPN: 0.902 % low: -9.351 % |
|